PDCD1 and hepatocellular carcinoma: The strategy of combining ICIs with anti-VEGF antibodies proved to be fruitful also in other studies, as the trial assessing the treatment based on anti-PD-1 antibody sintilimab combined with the anti-VEGF IBI305 (a bevacizumab biosimilar) demonstrated a statistically significant benefit compared to sorafenib in Chinese patients with HBV-related advanced HCC [46].